The top three Italian pharmaceutical companies together invoice 4 billion euros a year: what the American Pfizer accounts for in a month. In this great gap, the Italian pharmaceutical sector aims to grow thanks to development in foreign markets, the study of rare diseases and betting on research at home. A solution well understood by Menarini (2.8 billion euros in turnover), Recordati (747 million euros) and Sigma-Tau (615 million euros), companies with share capital and strictly family control. A path also followed by Pierrel, who recently landed in the USA, Chiesi with the Research Center, Bracco, specialized in contrast media and Dompé, which has invested in studies on multiple sclerosis. CorrierEconomia Pag.1 – 08/03/2010
